MoonLake Shares Drop After Upsized $200 Million Offering Priced at $20
MoonLake Immunotherapeutics' stock slipped after the company priced an enlarged public offering that will raise roughly $200 million before fees, with a pre-funded warrant component and a nearby close date. An insider sale under a pre-arranged trading plan added to selling pressure, anchoring the share price near the offering level even as U.S. ind…